Related references
Note: Only part of the references are listed.Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study
M. A. Paggiosi et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice
I. Baxter et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Adherence to raloxifene therapy: assessment methods and relationship with efficacy
J. Finigan et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)
Richard M. Jacques et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Bone turnover markers: use in osteoporosis
Kim Naylor et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
Treatment failure in osteoporosis
A. Diez-Perez et al.
OSTEOPOROSIS INTERNATIONAL (2012)
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis
Samuel Vasikaran et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
Bone Turnover Markers and Bone Mineral Density Response With Risedronate Therapy: Relationship With Fracture Risk and Patient Adherence
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
S. Vasikaran et al.
OSTEOPOROSIS INTERNATIONAL (2011)
A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy
A. Rogers et al.
BONE (2009)
Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results From the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) Study
Ronald Emkey et al.
CLINICAL THERAPEUTICS (2009)
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
P. Bergmann et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of Osteoporosis
Samuel D. Vasikaran
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study
Paul D. Miller et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial
DC Bauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide
R Eastell et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
M Arlot et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling
BL Riggs et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
TREATMENT WITH ONCE-WEEKLY ALENDRONATE 70 MG COMPARED TO ONCE-WEEKLY RISEDRONATE 35 MG IN WOMEN WITH POSTMENOPAUSALE OSTEOPOROSIS: A RANDOMIZED DOUBLE-BLIND STUDY
Peter Pietschmann
JOURNAL FUR MINERALSTOFFWECHSEL (2005)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial
DC Bauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
JJ Caro et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial
SL Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2002)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Preanalytical variability of biochemical markers of bone turnover
R Hannon et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy
E Fink et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
